Palo Alto Medical Foundation

Research Institute of Palo Alto Medical Foundation

Pfizer Corporation

Abbott Laboratories Corporation

Palo Alto Medical Research Foundation

Palo Alto Medical Foundation Research Institute

Jack S Remington

Fausto G Araujo

Jeffrey B Prince

Fausto G De Araujo

Somesh D Sharma

Georges Desmonts

Joan D Tyner

Jeffrey C Hunt

Gregory Thomas Maine

Lawrence V Howard

Linda E Chovan

Michael Jyh-Tsing Sheu

Susan Brojanac

Yashuhiro Suzuki

Philippe Thulliez

Yasuhiro Suzuki

Shuli Li

Fausto Araujo

Stephen F Parmley

Shuili Li

The present invention relates to combinations or mixtures of antigens which may be used in the detection of IgM and/or IgG antibodies to,as well as to the P35 antigen which may be used to distinguish acute from chronic toxoplasmosis. Furthermore, the present invention also relates to methods of using these combinations of antigens, antibodies raised against these combinations of antigens or against the novel P29 antigen thereof, as well as kits and vaccines containing the antigens present in the combinations.

Method of using P35 antigen of toxoplasma gondii in distinguishing acute from chronic toxoplasmosis

Genetic material encoding the P28 peptide of Toxoplasma gondii has been isolated and characterized. This genetic material allows the production of peptides for use in diagnosis or immunization or can itself be directly used in hybridization assays.

Toxoplasma gondii P28 polypeptides

A method of reducing the severity of toxoplasmosis resulting from infection of a patient with Toxoplasma gondii by administering to a patient in need of such treatment, either after infection or before exposure to infection, a therapeutically effective amount of a compound that is a spiropiperidyl derivative of rifamycin S, wherein the derivative comprises an imidazole ring that includes carbons at positions 3 and 4 of the rifamycin ring, the carbon at position 2 of the imidazole ring also being a ring carbon at position 4 of a piperidine ring system, thereby forming a spiropiperidyl ring system, the spiropiperidyl ring system optionally comprising a lower hydrocarbon substituent on the nitrogen of the piperidine.

Treatment for toxoplasmosis with a composition comprising a folate

Toxoplasma gondii P28 gene and methods for its use

Treatment for toxoplasmosis with a composition comprising a lincosamide

Treatment for toxoplasmosis with a composition comprising a sulfonamide

A method of reducing the severity of toxoplasmosis resulring from infection of a patient with Toxoplasma gondii by administering to a patient in need of such treatment, either after infection or before exposure to infection, a therapeutically effective amount of a compound that is a spiropiperidyl derivative of rifamycin S, wherein the derivative comprises an imidazole ring that includes carbons at positions 3 and 4 of the rifamycin ring, the carbon at position 2 of the imidazole ring also being a ring carbon at position 4 of a piperidine ring system, thereby forming a spiropiperidyl ring system, the spiropiperidyl ring system optionally comprising a lower hydrocarbon substituent on the nitrogen of the piperidine.

Treatment for toxoplasmosis with a composition comprising a macrolide

A method of reducing the severity of toxoplasmosis resulting from infection of a patient with Toxoplasma gondii by administering to a patient in need of such treatment, either after infection or before exposure to infection, a therapeutically effective amount of a compound that is a spiropiperidyl derivative of rifamycin S, wherein the derivative comprises an imidazole ring that includes carbons at positions 3 and 4 of the rifamycin ring, the carbon at position 2 of the imidazole ring also being a ring carbon at position 4 of a piperidine ting system, thereby forming a spiropiperidyl ring system, the spiropiperidyl ring system optionally comprising a lower hydrocarbon substituent on the nitrogen of the piperidine.

treatment for toxoplasmoisis with a composition containing a

Treatment for toxoplasmosis

Genetic material encoding the P22 peptide of Toxoplasma gondii has been isolated and characterized. This genetic material allows the production of peptides for use in diagnosis or immunization or can itself be directly used in hybridization assays.

Methods of detection of Toxoplasma gondii P22 gene

Nucleotide sequence encoding the Toxoplasma gondii P22 gene

A method of use of azithromycin or derivatives of azithromycin in the treatment of infection caused by Toxoplasma gondii in mammals is disclosed.

Azithromycin and derivatives as antiprotozoal agents

A method of detecting Toxoplasma infection and distinguishing acute infection from chronic infection is provided, comprising the steps of combining a sample suspected of containing antibodies to Toxoplasma antigens with a acute-phase-specific antigen reactive with an antibody specific for an acetone-treated Toxoplasma antigen under conditions favorable for formation of antigen-antibody complex, and detecting formation of the complex.

Method for the detection of acute-phase toxoplasma infection

An immunoassay for detecting disease associated Ig, such as IgM associated with acute forms of Toxoplasma gondii infection. Wells of microtiter plates are first coated with an antibody against the Ig to be detected and the test sample, e.g. serum, is then added and incubated. After removal of non-adsorbed materials from the wells, an insoluble visible form of the cognate antigen to the Ig, such as antigen fixed to latex particles, is added. If no such Ig is present in the sample, the antigen will appear as a smooth button on the bottom of the well; whereas if such Ig is present in significant quantity, the antigen will be captured by adsorbed antiIg-Ig complexes and distributed on the wall of the well according to the distribution of the antiIg-Ig complex thereon.

Immunoassay for detecting immunoglobulins and test kit

Growing community of inventors

Menlo Park, CA, United States of America

Jack S Remington